Chemistry:Tyloxapol
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
  (what is this?) (verify) | |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxapol are Exosurf and Alevaire.
References
- ↑ "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study". Journal of the National Medical Association 86 (1): 46–52. January 1994. PMID 8151722.
- ↑ "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest 101 (4): 1080–5. April 1992. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ↑ "Tyloxapol definition". Drugs.com. https://www.drugs.com/dict/tyloxapol.html.
- ↑ "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and Molecular Pathology 73 (2): 135–8. October 2002. doi:10.1006/exmp.2002.2449. PMID 12231215.
 |  |
